Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
about
Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentanClinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentanPharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsExploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitorPulmonary Arterial Hypertension among HIV-Infected Children: Results of a National Survey and Review of the LiteratureDual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertensionPharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.A review of pulmonary arterial hypertension: role of ambrisentan.Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Role of ambrisentan in the management of pulmonary hypertension.Association of CYP2C9*2 with bosentan-induced liver injury.Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.An atypical presentation of liver enzyme elevation resulting from bosentan use.Leads for the treatment of pulmonary hypertension.Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.Contraception in women with cardiac disease.Bosentan for chronic thromboembolic pulmonary hypertension.Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide.The management of acute pulmonary arterial hypertension.Evaluation of models for predicting drug-drug interactions due to induction.Bosentan for the treatment of adult pulmonary hypertension.Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
P2860
Q26851546-771EFCC8-D793-4A41-8CEF-86A6642BC4BCQ33161210-CDF3D5C7-9495-4D7C-B6EE-0E34611BA678Q33588179-04E2C230-446A-429A-AF25-5901113A4B45Q33655897-49DCADFB-E1F5-4202-9675-04AF349094BCQ33903698-D1A57E59-96C2-4A67-A890-AE50E069FF2BQ33938396-961F394D-B574-4169-A5BA-1902599AB512Q34133301-DF67AD69-8AD5-4CD2-B5B7-537D6CBE9780Q34344390-3A7E0D32-423D-49AB-AB47-F8D278514B5FQ34471194-D7AFAE35-6996-48E8-A911-B151F7F4D694Q34570893-6F9A765C-849B-48D6-BB54-08611B7B0115Q35290066-2A198EE1-6B51-4660-84F3-2839088CE7F9Q35296597-438DD2CD-EEDC-4CBE-8E4D-D76BA67BBE29Q35620058-F959ADC7-B653-4630-A1D6-BF2B9F4F35CFQ35827121-915CD67E-0AED-47E4-B1F7-9F6BF9B9C03DQ35846126-4307CB46-E7F0-4D1B-A149-C3BC87CE961AQ36013108-80027613-B38B-49DB-A71B-03D1AB4211FBQ36013161-CB88ACFA-4E8D-4454-AC43-4E5B2653E369Q36212186-8C605838-C459-4225-90FD-242DB3EFC8B0Q36491793-4F0B0F52-395E-44D2-BE69-A800685679E9Q36543145-63C2229A-C6C3-41A1-B23B-5E0F129AA2FEQ37201680-30E1AC22-E6DC-4D08-A044-A682160F02EDQ37302470-B10B3B30-ABB3-4AD2-845D-1D8AADF85E0BQ37310683-3E0AB85F-6EF1-49AD-9104-E284F4501361Q37325319-F245B1FE-2236-43A0-BFEA-BB2580790FD5Q37403190-FC53613C-094E-4264-9423-A3163ADB3DE6Q37425466-A1B4F450-1036-4C45-872C-DECFA1AFD4B3Q37481343-95E80F98-EF50-4619-A685-6ADFEDC6C465Q37492042-C6B44030-D4F7-4C05-9349-4D55FA1F5111Q37515708-19BCE291-AD1A-4A25-A5F5-CB3667D97CE1Q37608404-BEE2683C-6A2A-4E2A-99C6-323642D488FAQ37642817-A855976A-C1B0-47A3-91DA-DEFDBE7177EDQ37695883-7B6C1451-165C-4669-8D5A-494AE0CD9B13Q37766261-FEDD0341-5793-4EBA-A857-9C605C7EFFA4Q37800932-DC7C2EA3-4803-437A-8948-F14D9C7A9D24Q37822722-5C7DBB77-B5F1-4C2A-8E65-B82BEFDFAB99Q37841614-0214C222-D223-4008-B0AE-210024DE79F2Q37879213-44855D99-E8FE-47E6-A0D3-EEF90958B642Q37955160-0931907B-D060-4680-B765-7A58CD2D0B6CQ38028549-8DE6C1C5-0BE5-4943-B2E5-77FD631454D9Q38056878-6A86A00A-E07B-4E4C-A312-DD6DD1D0F071
P2860
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
@ast
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
@en
type
label
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
@ast
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
@en
prefLabel
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
@ast
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
@en
P1476
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
@en
P2093
Jasper Dingemanse
Paul L M van Giersbergen
P304
P356
10.2165/00003088-200443150-00003
P577
2004-01-01T00:00:00Z
P6179
1016126095